Tiblio
Sign Up

TLPH

Talphera Inc.
NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$61.76M
P/E Ratio
—
EPS
$-0.28
Beta
0.70
52W High
$1.57
52W Low
$0.38
50-Day MA
$0.90
200-Day MA
$0.99
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.02
PEG Ratio
—

About Talphera Inc.

Talphera Inc. is an innovative biotechnology firm focused on developing cutting-edge peptide-based therapies aimed at rare diseases and substantial unmet medical needs. The company’s robust pipeline, particularly in the realm of novel cancer treatments, underscores its potential for significant growth in the biopharmaceutical sector. With a strong commitment to research and a mission to deliver transformative health solutions, Talphera presents an attractive investment opportunity for institutional investors interested in the evolving landscape of biotechnology.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)1,000
Gross Profit (TTM)-726,000
EBITDA$-15.16M
Operating Margin-1451600.00%
Return on Equity-118.40%
Return on Assets-40.20%
Revenue/Share (TTM)$0.00
Book Value$0.34
Price-to-Book3.00
Price-to-Sales (TTM)61760.59
EV/Revenue34424.62
EV/EBITDA0.11
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$51.90M
Float$26.98M
% Insiders21.41%
% Institutions34.76%

Historical Volatility

HV 10-Day
58.26%
HV 20-Day
77.84%
HV 30-Day
72.51%
HV 60-Day
69.32%
HV Rank
44.8%

Volatility is currently contracting

Analyst Ratings

Consensus ($3.17 target)
1
Strong Buy
1
Buy

Latest News

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.

PRNewsWire5/13/2026Neutral
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 financial results after market close on Wednesday, May 13, 2026, then host a live webcast and conference call at 4:30 p.m.

PRNewsWire5/7/2026Neutral

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/SAMGNAmgen IncTMOThermo Fisher Scientific IncGILDGilead Sciences IncABTAbbott Laboratories
View all HEALTHCARE stocks →
Data last updated: 7/9/2026